Abstract:Targeted protein degradation (TPD) represents a promising alternative to conventional occupancy-driven protein inhibition. Despite the existence of more than 600 E3 ligases in the human proteome, so far only a few have been utilized for TPD of histone deacetylases (HDACs), which represent important epigenetic anticancer drug targets. In this study, we disclose the first-in-class Fem-1 homolog B (FEM1B)-recruiting HDAC degraders. A set of twelve proteolysis targeting chimeras (PROTACs) was synthesized using a solid-phase supported parallel synthesis approach utilizing a covalent FEM1B ligand as E3 ligase warhead. The evaluation of the HDAC degradation efficiency revealed substantial HDAC1 degradation by the top performing degrader FF2049 (1g: Dmax = 85%; DC50 = 257 nM). Unlike our previously published cereblon-recruiting selective HDAC6 degrader, A6, which uses the same HDAC ligand, the FEM1B-based PROTACs achieved selective HDAC1-3 degradation. This unexpected change in HDAC isoform degradation profile was accompanied by significant enhancement of the anticancer properties.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a new targeted protein degradation (TPD) method, specifically using Fem - 1 homolog B (FEM1B) to recruit histone deacetylase (HDAC) degraders. Specifically, the researchers designed and synthesized 12 different proteolysis - targeting chimeras (PROTACs). These PROTACs can specifically degrade HDACs, especially HDAC1 - 3, by recruiting FEM1B. This research aims to expand the range of E3 ubiquitin ligases used for HDAC degradation and improve the selectivity for specific HDAC subtypes, thereby enhancing anti - tumor activity. ### Main problems 1. **Expand the range of use of E3 ubiquitin ligases**: Currently, the E3 ubiquitin ligases used for HDAC degradation are mainly limited to cereblon (CRBN), Von Hippel - Lindau (VHL), and cellular inhibitor of apoptosis protein (cIAP). The researchers hope to expand the types of E3 ubiquitin ligases available for PROTACs by introducing FEM1B as a new E3 ubiquitin ligase. 2. **Improve the selectivity of HDAC degradation**: Traditional HDAC inhibitors are usually non - selective, while PROTACs can be designed to selectively degrade specific HDAC subtypes. The researchers hope to develop PROTACs that can specifically degrade HDAC1 - 3 to improve their effectiveness in cancer treatment. 3. **Enhance anti - tumor activity**: By designing efficient PROTACs, the researchers hope to significantly improve their anti - tumor activity, especially showing stronger anti - proliferative effects in multiple cancer cell lines. ### Research methods - **Design and synthesis**: The researchers designed 12 different PROTACs. These PROTACs contain a non - selective HDAC inhibitor (such as vorinostat) as a POI ligand and a FEM1B recruiter (such as EN106). These compounds were prepared by solid - phase synthesis methods. - **Biological evaluation**: The anti - proliferative activity and HDAC degradation efficiency of these PROTACs were evaluated by methods such as cell viability assays, Western blot analysis, and Simple Western immunoassay. ### Main findings - **Efficient degradation of HDAC1 - 3**: One of the PROTACs (FF2049, i.e., 1g) showed the highest HDAC1 degradation efficiency (Dmax = 85%, DC50 = 257 nM) and was highly selective for HDAC1 - 3 without affecting other HDAC subtypes. - **Enhanced anti - tumor activity**: Compared with the previous CRBN - based HDAC6 - selective degrader A6, the FEM1B - recruited PROTACs showed stronger anti - proliferative activity in multiple cancer cell lines. - **Cell selectivity**: These PROTACs showed different degradation efficiencies in different types of cancer cell lines, indicating that they have certain cell selectivity. ### Conclusion This research has successfully developed the first class of FEM1B - recruited HDAC degraders. These degraders can not only efficiently degrade HDAC1 - 3 but also show significant anti - tumor activity. This achievement provides new ideas and methods for the development of more effective anti - tumor drugs.

Development of the First-in-Class FEM1B-Recruiting Histone Deacetylase Degraders

Development and characterization of the first selective class IIb histone deacetylase degraders

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Advances in the Design and Development of PROTAC-mediated HDAC degradation.

Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands

Cell-Specific Degradation of Histone Deacetylase Using Warhead-Caged Proteolysis Targeting Chimeras

Discovery and Characterization of Active CBP/EP300 Degraders Targeting the HAT Domain

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation

Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3

Discovery of the First-in-class G9a/GLP PROTAC Degrader

Degraders in epigenetic therapy: PROTACs and beyond

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

ByeTAC: Bypassing an E3 Ligase for Targeted Protein Degradation

Design, synthesis and biological evaluation of new RNF126-based p300/CBP degraders

Design, synthesis, and biological evaluation of Wee1 kinase degraders

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Development of the First-in-Class Degrader of NLRP3

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.